ADRUXE DIN 02565781
Health Canada record
| Active ingredient(s) | RITUXIMAB 10 MG |
|---|---|
| Dosage form | Solution |
| Route | Intravenous |
| Schedule | SCHEDULE D; PRESCRIPTION |
| Class | Human |
| ATC | L01FA01 RITUXIMAB |
| Original market date | |
| Current status date | 13-Feb-2026 |
| Source | Health Canada DPD |
Establishment licence of the holder
Dr. Reddy's Laboratories Canada Inc — licence 102182, currently licensed, last inspection rating C (2025-05-06).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing RITUXIMAB
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02241927 | RITUXAN | HOFFMANN-LA ROCHE LIMITED | Solution | RITUXIMAB 10 MG | Marketed |
| 02457350 | RITUXAN SC | HOFFMANN-LA ROCHE LIMITED | Solution | RITUXIMAB 1400 MG | Marketed |
| 02473976 | RITUXAN SC | HOFFMANN-LA ROCHE LIMITED | Solution | RITUXIMAB 1600 MG | Marketed |
| 02498316 | RIXIMYO | SANDOZ CANADA INCORPORATED | Solution | RITUXIMAB 10 MG | Marketed |
| 02495724 | RUXIENCE | PFIZER CANADA ULC | Solution | RITUXIMAB 10 MG | Marketed |
| 02478382 | TRUXIMA | CELLTRION INC. | Solution | RITUXIMAB 100 MG | Marketed |
| 02478390 | TRUXIMA | CELLTRION INC. | Solution | RITUXIMAB 500 MG | Marketed |
| 02513447 | RIABNI | AMGEN CANADA INC | Solution | RITUXIMAB 10 MG | Cancelled Post Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 37043 | 2026-02-13 | New Drug Submission (NDS) |
International API supply for RITUXIMAB
0 active FDA Drug Master Files.
Request a quote for ADRUXE